Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Penumbra (PEN) to $260 from $240 and keeps an Equal Weight rating on the shares following a Q4 report the firm calls “solid overall, with particularly impressive numbers in US thrombectomy.” 2025 guidance is “a little light on the topline,” but this is likely driven by the company’s “conservative guidance philosophy,” says the analyst, who sees limited upside to the current valuation.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Penumbra price target raised to $328 from $305 at Baird
- Penumbra price target raised to $320 from $305 at UBS
- Penumbra price target raised to $340 from $323 at Canaccord
- Buy Rating Reaffirmed for Penumbra: Strong Financial Performance and Promising Growth Prospects Drive Upgraded Price Target
- Analyst’s Hold Rating on Penumbra Amid Strong Q4 Performance and Uncertain 2025 Outlook